Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07059156RecruitingPhase 2/Phase 3
Chemotherapy and transplant for adult ALL
This trial is testing a combination of chemotherapy and stem cell transplant for adults with Acute Lymphoblastic Leukemia (ALL). It aims to find the best way to treat ALL and improve survival. If you are diagnosed with ALL and are between 18 and 60 years old, you may be a candidate.
Taiyuan, ShanxiAges 18–60 - NCT07059975RecruitingEarly Phase 1
Better monitoring and treatment for pediatric AML
This trial tests a new way to monitor and treat children and young adults with acute myeloid leukemia (AML) or myeloid sarcoma. It aims to improve outcomes by using personalized treatment adjustments based on how well the disease responds to initial therapy.
Houston, TexasAges 1 month–30 years - NCT07062250Recruiting
Home blood tests and transfusions for new AML patients
This trial tests whether people with newly diagnosed AML can safely check their own blood counts at home and receive transfusions there while getting chemotherapy at home. If it works, you may need fewer hospital visits.
CopenhagenAges 18 years+ - NCT07066397RecruitingPhase 1
CAR-T cell therapy for relapsed B-cell ALL
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
TaipeiAges 18 years+ - NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new treatment called CTD402 for people with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to other treatments. It looks at whether adding a donor stem cell transplant after CTD402 can help control the disease.
Palo Alto, CaliforniaAges 12 years+ - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT07075016RecruitingPhase 3
IDH1 mutation targeted therapy for untreated AML
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
FeldkirchAges 18 years+ - NCT07078591RecruitingPhase 2
Venetoclax with mini transplant for new AML
This trial tests combining the medicine Venetoclax with a mini stem-cell transplant from a partially matched relative for people with newly diagnosed acute myeloid leukemia (AML). It may help control the leukemia while reducing transplant side effects.
BeijingAges 18 years+ - NCT07085559RecruitingEarly Phase 1
Metabolically armed BCMA CAR-T for relapsed plasma cell cancer
This trial tests a new type of CAR-T cell therapy (Meta10-BCMA) that is "metabolically armed" to better fight cancer cells. It's for people with plasma cell cancers that have come back or not responded to multiple prior treatments, and whose cancer cells carry the BCMA protein.
Hefei, AnhuiAges 19–75 - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07121140Recruiting
Home blood transfusions for cancer patients
This trial tests whether it is safe to give blood transfusions at home instead of in the hospital. It is for people who need regular blood transfusions for their cancer care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT07130695RecruitingPhase 1
Olutasidenib for IDH1-mutated AML after initial treatment
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
Richmond, VirginiaAges 18 years+ - NCT07131254RecruitingEarly Phase 1
Study of GT719 cell therapy for CD19-positive leukemia or lymphoma
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
Ganzhou, JiangxiAges 18–75 - NCT07132684RecruitingPhase 3
Comparing two chemotherapy plans for older AML patients
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
TianjinAges 55–75 - NCT07147621Recruiting
Chemotherapy and thinking changes in blood cancer treatment
This study looks at whether chemotherapy for blood cancers like leukemia and lymphoma can affect thinking, memory, or concentration. It compares patients to a close family member or friend to see if any changes are related to the treatment.
Angers, Maine et LoireAges 18 years+ - NCT07153068RecruitingPhase 1/Phase 2
SupCD7 CART therapy for CD7 positive blood cancers
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07172204RecruitingPhase 2
Alternating chemo drugs for older or frailer adults with new AML
This trial tests a combination of two chemotherapy regimens given in turns for people with newly diagnosed acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The goal is to find a gentler but effective treatment option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07202052RecruitingPhase 2/Phase 3
Antibiotics or immunoglobulin for infections in blood cancer
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
Adelaide, South AustraliaAges 18 years+ - NCT07202065RecruitingPhase 2/Phase 3
Preventing infections with antibiotics or immunoglobulin in blood disorders
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Adelaide, South AustraliaAges 18 years+
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,319 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.